1. India Stocks

  2. •

    Healthcare

  3. •

    Medical - Healthcare Information Services
Indegene Limited

Indegene Limited

INDGN.BO
Indegene LimitedIN flagBombay Stock Exchange
494.25
INR
+2.95
- -
119.27BMarket Cap
Indegene Limited
INDGN.BO
(Bombay Stock Exchange)

Recent

price

494.25

P/E

ratio

- -

div

yld

- -

ROIC.AI

2021
2022
2023
2024
2025
2026
TTM
FRC
40.38
69.57
96.38
108.4
119.73
146.34
122.22
Revenue per Share
6.24
6.89
11.12
14.09
17.15
16.72
18.2
Basic EPS, GAAP
6.33
11.38
4.66
20.8
17.37
25.28
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
2
- -
Dividend per Share
12.56
19.61
32.6
1.86
2.02
2.01
- -
Book Value per Share
12.27
29.51
22.79
37.58
87.41
63.41
- -
Tangible Book Value per Share
239
239
239
239
237
240
239
Basic Weighted Avg Shares
9,663
16,646
23,061
25,896
28,393
35,105
29,236
Sales/Revenue/Turnover
22.69
15.26
14.58
16.79
15.99
14.03
16.38
Operating Margin (%)
346
335
598
761
802
1,265
817
Depreciation Expense
1,494
1,648
2,661
3,367
4,067
4,011
4,354
Net Income, GAAP
19.78
28.11
26.69
26.58
24.59
23.6
23.85
Effective Tax Rate (%)
15.46
9.9
11.54
13
14.32
11.43
14.89
Profit Margin (%)
2,599
6,896
9,596
11,799
19,655
15,322
- -
Working Capital
311
439
4,795
3,986
724
1,050
- -
LT Debt
3,331
7,639
10,637
14,291
26,156
31,387
- -
Total Equity
- -
29.63
20.38
18.24
14.71
12.43
- -
Return on Invested Capital (%)
- -
37.98
31.8
40.81
123.86
243.18
731.7
Return on Capital (%)
- -
42.8
42.6
81.67
881.26
835.62
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'25
Jun'26
ST Debt
- -
292
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
724
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
240
- -
Market Capitalization
142,797
137,148
137,423

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'25
Jun'26
Total Current Assets
- -
25,300
- -
Cash, Cash Equivalents & STI
- -
16,769
- -
Accounts Receivable, Net
- -
6,322
- -
Inventories
- -
- -
- -
Total Current Liabilities
- -
5,645
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
292
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
61.19%
20%
Free Cash Flow
- -
79.4%
47.22%
Net Income, GAAP
- -
23.55%
-1.38%
Sales/Revenue/Turnover
- -
31.28%
23.64%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
6,075
6,357
6,734
6,730
25,896
2025
6,765
6,868
7,204
7,556
28,393
2026
7,608
9,421
10,034
- -
35,105

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2.86
3.13
4.14
- -
14.09
2025
3.79
3.84
4.59
4.91
17.15
2026
4.86
4.29
3.32
- -
16.72

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
2
Similar Companies
Mach7 Technologies Limited (M7T.AX)
MedPeer,Inc. (6095.T)
CSAM Health Group AS (CSAMF)
Bullfrog AI Holdings, Inc. Common Stock (BFRG)
IntelliCentrics Global Holdings Ltd. (6819.HK)
MobileSmith, Inc. (MOSTQ)
Business
Indegene Limited (INDGN.BO), founded in 1998 and headquartered in Bengaluru, India, provides technology-driven solutions and services to biopharmaceutical, emerging biotech, and medical device companies worldwide, with operations across North America, Europe, Asia-Pacific, and India; its core offerings encompass digital health solutions including AI and machine learning platforms for patient insights and process optimization, patient engagement solutions, commercialization services such as regulatory affairs, pharmacovigilance, medical writing, clinical trial management, and enterprise clinical solutions, technology platforms for cloud-based collaboration and data sharing, consulting services for strategic business performance improvement, and multichannel marketing with AdTech capabilities. The company serves the life sciences industry through segments focused on drug development, clinical operations, regulatory compliance, market access, pricing strategy, and healthcare communications for pharmaceutical marketing. In recent developments, Indegene expanded its portfolio through strategic acquisitions including BioPharm Communications for up to $106 million in October 2025 to bolster AI-led marketing and digital advertising in the US, Cake Group for up to EUR 8.5 million announced in November 2025 to strengthen healthcare marketing in Europe's DACH region with completion expected in January 2026, and earlier purchases of WARN & CO, while reporting robust revenue growth including approximately $600 million in fiscal 2024 following its May 2024 IPO raising ₹1,842 crore and supported by prior investments like $200 million from Carlyle Group and Brighton Park Capital in 2021.